News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InterMune, Inc. (ITMN) CEO: Bittersweet Ending To A Biotech Comeback Story



8/26/2014 6:33:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

InterMune Inc.’s comeback story — from a drug rejection by the FDA to an $8.3 billion buyout offer Sunday from drug giant Roche — is mixed for Dan Welch. After shedding some of the Brisbane company’s (NASDAQ: ITMN) key assets, focusing resources on a huge, new study and convincing investors to pony up more cash to support the effort, Welch and much of his leadership team may be out of jobs in a few months.

Hey, check out all the research scientist jobs. Post your resume today!

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES